Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GOAL II: Gemcitabine/Oxaliplatin/Rituximab with Tafasitamab in Relapsed/Refractory Aggressive or Transformed B-cell Lymphoma
2019-002373-59Phase 2Active
- Sponsor
- University Medical Center Mainz
- Start
- Jul 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tafasitamab in mature B-cell lymphoma and transformed B-cell lymphoma, sponsored by University Medical Center Mainz. Primary endpoint: Objective response rate within first 8 treatment cycles (Lugano criteria). Started Jul 2020; status: active.
02
Drugs
tafasitamab
03
Conditions
mature B-cell lymphomatransformed B-cell lymphoma
Beyond the preview
Go deeper on 2019-002373-59.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002373-59.